Wall Street brokerages forecast that Viela Bio, Inc. (NASDAQ:VIE) will announce sales of $5.10 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Viela Bio’s earnings. The highest sales estimate is $6.00 million and the lowest is $3.90 million. The business is expected to issue its next quarterly earnings report on Wednesday, March 24th.
On average, analysts expect that Viela Bio will report full year sales of $8.06 million for the current fiscal year, with estimates ranging from $6.22 million to $9.29 million. For the next year, analysts expect that the company will report sales of $63.50 million, with estimates ranging from $44.44 million to $83.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Viela Bio.
Several analysts have recently weighed in on the stock. HC Wainwright decreased their price target on shares of Viela Bio from $75.00 to $52.00 and set a “buy” rating for the company in a research note on Thursday, November 12th. BidaskClub raised shares of Viela Bio from a “sell” rating to a “hold” rating in a research note on Thursday, November 5th.
About Viela Bio
Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases.
Further Reading: Understanding the two types of arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.